DB
Therapeutic Areas
Ocean Biomedical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OCEA-001 (anti-CSPG4 mAb) | Non-Small Cell Lung Cancer (NSCLC), Melanoma | Phase 1b/2 |
| B7-H3 Targeted Antibody | Solid Tumors | Preclinical |
| GMZ2.6C Fusion Protein | Malaria Prevention & Treatment | Preclinical |
| Fibrosis Small Molecule Program | Idiopathic Pulmonary Fibrosis (IPF), Liver Fibrosis | Discovery/Preclinical |
Leadership Team at Ocean Biomedical
DC
Dr. Chirinjeev Kathuria, MD
Co-Founder and Executive Chairman
DS
Dr. Suren Ajjarapu, PhD
Co-Founder, Chief Executive Officer, and Chairman
EN
Elizabeth Ng
Chief Financial Officer
DM
Dr. Michael J. Manyak, MD
Chief Medical Officer
DJ
Dr. Jack A. Elias, MD
Co-Founder and Chairman of Scientific Advisory Board
DJ
Dr. Jake Kurtis, PhD
Scientific Founder, Director of Center for International Health Research at Brown University
DI
Dr. Inder Singh
Board Director